As medical devices become more intricate, packaging evolves with high-barrier films, specialized inert gases, and nano-coatings. Global R&D centers expand capacity for sterilization innovation, motivated by growing patient needs and clinical safety standards. Worldwide, intelligent packaging solutions continue to flourish.New Delhi, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The global medical device packaging market is projected to grow from US$ 32.87 billion in 2024 to US$ 59.82 billion by 2033, at a CAGR of 6.88% ...

Global Pediatric Cancer Biomarkers Market Global Pediatric Cancer Biomarkers Market Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Pediatric Cancer Biomarkers Market by Indication, Biomarker, End User, and Region" report has been added to ResearchAndMarkets.com's offering. This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.The global pediatric cancer biomarkers market size was estimated to be USD 0.888 billion in 2023 and is expected to rea ...

Press ReleaseOpenreach chooses Nokia to build open-access fiber network to connect millions to faster broadband Nokia building open access platform to accelerate fiber broadband services for millions of UK homes and businesses.Nokia’s intent-based model enables Openreach to reduce operations support systems (OSS) complexity by 85%. Nokia’s domain controllers allow Openreach to fully automate and simplify network operations, driving scalability and operational efficiency throughout its network. 9 January 202 ...

Market Overview - The global PARP inhibitor biomarkers market was valued at USD 0.985 billion in 2024 and is projected to reach USD 2.43 billion by 2035, growing at a CAGR of 8.57% during the forecast period (2025-2035) [3] - The market growth is driven by rising cancer rates, increasing adoption of precision medicine, advancements in genomic research, more FDA approvals, expanding indications, partnerships, collaborations, and government funding [3] Key Players - The report includes detailed profiles of major industry players such as AstraZeneca, GlaxoSmithKline (GSK), Pfizer, Inc., Merck & Co., Inc., Clovis Oncology, Novartis International AG, Roche Holding AG, and Bristol-Myers Squibb [1] Market Segmentation by Product - The kits segment accounted for the highest revenue in 2024 due to the widespread adoption of ready-to-use diagnostic kits in clinical settings [5] - The assays segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing demand for high-precision testing methods and advancements in assay technologies [5] Market Segmentation by Service - The BRCA 1 & 2 testing segment generated the highest revenue in 2024, attributed to the high prevalence of BRCA mutations in breast and ovarian cancers [6] - The HRD testing segment is predicted to grow at the fastest CAGR, reflecting the focus on identifying broader patient populations beyond BRCA mutations [6] Market Segmentation by Application - The breast cancer segment led the market in revenue in 2024, driven by the high incidence of breast cancer and growing adoption of PARP inhibitors for BRCA-mutated patients [7] - The ovarian cancer segment is expected to grow at the fastest CAGR, supported by expanding use of PARP inhibitors and increasing research into biomarkers [7] Market Segmentation by End-User - Hospitals and clinics accounted for the highest revenue in 2024, due to high patient volume and preference for hospitals for cancer diagnosis and treatment services [8] - Diagnostic laboratories are predicted to grow at the fastest CAGR, driven by the outsourcing of specialized biomarker testing services and demand for high-throughput diagnostics [8] Regional Analysis - North America is anticipated to hold the highest revenue share during the forecast period, supported by well-established healthcare infrastructure, high adoption of precision medicine, and presence of leading pharmaceutical companies [9] - The Asia Pacific region is expected to grow at the fastest CAGR, driven by rapidly expanding healthcare infrastructure, increasing awareness of cancer diagnostics, rising healthcare spending, and a growing patient population [9] Technological Advancements - The introduction of the PARP Activity Screening and Inhibitor Testing Assay (PASTA) in January 2023 has advanced the understanding of PARP-related therapies and improved treatment precision [5] - Genome-wide CRISPR knockout screens have identified novel markers of prostate cancer resistance to PARP inhibitors, such as the MMS22L gene [9]

To Nasdaq Copenhagen A/S 9th January 2025 Announcement no. 3/2025CORRECTION: ISIN DK0009416893 is a Realkreditobligation (RO)Final terms for bonds to be listed 10th January 2025On 10th January 2025, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bonds consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage B ...

Understand the significant growth trajectory of the Diabetes Management Application segment, which is expected to reach US$11.5 Billion by 2030 with a CAGR of a 22.2%. The COPD Application segment is also set to grow at 20.3% CAGR over the analysis period. Gain insights into the U.S. market, estimated at $1.7 Billion in 2023, and China, forecasted to grow at an impressive 20.7% CAGR to reach $3.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pac ...

BENGALURU, India, Jan. 9, 2025 /PRNewswire/ -- Zoomcar Holdings, Inc. (NASDAQ: ZCAR) ("Zoomcar", or "we", or "our"), the leading marketplace for car sharing in India, proudly announces a milestone achievement in its financial performance in select unaudited and unreviewed financial results for the third fiscal quarter ended December 31, 2024. The company recorded its highest-ever unaudited and unreviewed contribution profit for the single month in December 2024, amounting to $494,506 based on provisional fi ...

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "6G Market 2025-2029" report has been added to ResearchAndMarkets.com's offering.The 6G market is forecasted to grow by USD 32.7 billion during 2024-2029, accelerating at a CAGR of 3.1% during the forecast period. This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the late ...

Medical Innovation and Research - King Faisal Specialist Hospital & Research Centre (KFSHRC) has been recognized for its study on fully robotic liver transplants, which was named one of the Top 10 Most Impactful Papers of 2024 by the American Society of Transplantation [1] - The study, titled "Outcomes of Fully Robotic Recipient Living Donor Liver Transplant about the Open Approach," represents the world's first series of fully robotic recipient liver transplants from living donors [1] - The study highlighted significant advancements in robotic-assisted liver transplantation, including reduced blood loss, shorter hospital stays, and improved cosmetic outcomes compared to traditional open surgery, without increasing complication rates [1] Leadership and Expertise - Professor Dr Dieter Broering, the Executive Director of the Organ Transplant Centre of Excellence at KFSHRC, spearheaded the world's first fully robotic left lobe liver transplant in 2024 [2] - Dr Broering emphasized the transformative potential of robotic transplants, particularly for high-risk procedures, and reaffirmed the commitment to delivering safer, faster, and more effective outcomes for patients worldwide [2] Academic and Industry Recognition - The study was published in the Transplantation Journal, a leading platform for pioneering research with over 58 years of history and 25,000 annual citations [3] - KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centres for the second consecutive year [4] - KFSHRC was recognized as the most valuable healthcare brand in the Kingdom and the Middle East according to the 2024 Brand Finance rankings and was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine [4]

Understand the significant growth trajectory of the Glass Material segment, which is expected to reach US$2.0 Billion by 2030 with a CAGR of a 7.2%. The Plastic Material segment is also set to grow at 5.6% CAGR over the analysis period. Gain insights into the U.S. market, estimated at $474.2 Million in 2023, and China, forecasted to grow at an impressive 10.3% CAGR to reach $686.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Pharmaceut ...